Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease
被引:86
作者:
Marzolo, Maria-Paz
论文数: 0引用数: 0
h-index: 0
机构:
Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, FONDAP Ctr Cell Regulat & Pathol CRCP, Santiago, Chile
MIFAB, Santiago, ChileWashington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA
Marzolo, Maria-Paz
[2
,3
]
Bu, Guojun
论文数: 0引用数: 0
h-index: 0
机构:
Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA
Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA
Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63110 USAWashington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA
Bu, Guojun
[1
,4
,5
]
机构:
[1] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA
Amyloid-beta (A beta) peptide accumulation in the brain is central to the pathogenesis of Alzheimer's disease (AD). A beta is produced through proteolytic processing of a transmembrane protein, beta-amyloid precursor protein (APP), by beta- and gamma-secretases. Mounting evidence has demonstrated that alterations in APP cellular trafficking and localization directly impact its processing to A beta. Members of the low-density lipoprotein receptor family, including LRP, LRP1B, SorLA/LR11, and apoER2, interact with APP and regulate its endocytic trafficking. Additionally, APP trafficking and processing are greatly affected by cellular cholesterol content. In this review, we summarize the current understanding of the roles of lipoprotein receptors and cholesterol in APP trafficking and processing and their implication for AD pathogenesis and therapy. (C) 2008 Elsevier Ltd. All rights reserved.